Patents for A61P 35 - Antineoplastic agents (221,099)
12/2007
12/06/2007WO2007138994A1 Hsp90 inhibitor
12/06/2007WO2007138705A1 Tumor suppressor
12/06/2007WO2007138472A2 Triazolopyridazine derivatives
12/06/2007WO2007138355A1 Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
12/06/2007WO2007138334A2 Methods for identifying an agent that modulates type i or type ii pip kinase activity or expression
12/06/2007WO2007138277A1 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation
12/06/2007WO2007138268A1 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation
12/06/2007WO2007138116A2 Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
12/06/2007WO2007138023A1 Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
12/06/2007WO2007138017A1 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors
12/06/2007WO2007137981A1 Inhibitors of tyrosine kinases
12/06/2007WO2007137833A1 Specifically adapted plant-derived redox catalyst and method for the production thereof
12/06/2007WO2007137738A1 Spirocyclic nitriles as protease inhibitors
12/06/2007WO2007137513A1 A TYPE OF NOVEL 2'-α-HYDROXYALKYL TAXEL COMPOUNDS AND THE PREPARATION METHODS THEREOF
12/06/2007WO2007137427A1 Bioactive purified hspe7 compositions
12/06/2007WO2007137414A1 Overexpression of integrin linked kinase (ilk) to improve post-infarct remodeling
12/06/2007WO2007137342A1 Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
12/06/2007WO2007117398A3 Non-peptidic molecules for detecting and treating tumors
12/06/2007WO2007110649A3 Process for the preparation of 2,6,9-trisubstituted purines
12/06/2007WO2007109142A3 M3 muscarinic receptor antagonists for treating tumors
12/06/2007WO2007107748A3 Inhibition of tumour growth
12/06/2007WO2007084667A3 Fused heterobicyclic kinase inhibitors
12/06/2007WO2007061737A3 FUSED BICYCLIC mTOR INHIBITORS
12/06/2007WO2007055773A3 Use of inhibitors of pi3k-c2a for the treatment of apoptos i s-related disorders
12/06/2007WO2007039919A8 Crystalline forms of anastrozole
12/06/2007WO2004060304A3 Novel compositions and methods in cancer
12/06/2007WO2003023001A3 Novel proteins and nucleic acids encoding same
12/06/2007US20070282100 Boronic ester and acid compounds, synthesis and uses
12/06/2007US20070282015 Novel Splice Variants of Human Dkkl1
12/06/2007US20070281991 Preparation Of Phenol-Amide Compounds With Anti-Oxidizing Properties
12/06/2007US20070281963 tyrosine kinase inhibitors such as 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(3-morpholin-4-ylpropoxy)-2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one, used as anticarcinogenic or antiproliferative agents
12/06/2007US20070281948 Substituted 2-pyridone derivatives, method for their preparation and their use as medicament
12/06/2007US20070281934 Indole derivatives as inhibitors of histone deacetylase
12/06/2007US20070281919 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands
12/06/2007US20070281911 Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis
12/06/2007US20070281898 Vector
12/06/2007US20070281889 Parathyroid hormone receptor activation and stem and progenitor cell expansion
12/06/2007US20070281041 Compositions and Methods Involving MDA-7 for the Treatment of Cancer
12/06/2007US20070281040 Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
12/06/2007US20070281028 Drug Delivery of a Cox Inhibitor from Embolic Agents
12/06/2007US20070280969 RSF-1 as a prognostic marker and therapeutic target
12/06/2007US20070280958 homodimer-forming chemokines such as Chemokine (C-C motif) ligand 2 (CCL2) having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds; for inflammatory, autoimmune, or infectious diseases
12/06/2007US20070280952 Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance and immunogenicity; antiproliferative disorders
12/06/2007US20070280951 Cell Death Inducing Agents
12/06/2007US20070280946 Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof
12/06/2007US20070280939 Prostatic Acid Phosphatase Antigens
12/06/2007US20070280937 Compositions and Methods for the Treatment and Diagnosis of Neoplastic and Infectious Diseases
12/06/2007US20070280932 Binding to monoclonal antibodies; antitumor agents
12/06/2007US20070280931 Antibody variants
12/06/2007US20070280929 Adjuvant in the form of a lipid-modified nucleic acid
12/06/2007US20070280928 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
12/06/2007US20070280918 Multitherapy Against Cancer
12/06/2007US20070280907 Adult bone marrow cell transplantation to testes creation of transdifferentiated testes germ cells, leydig cells and sertoli cells
12/06/2007US20070280886 Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
12/06/2007US20070280881 Dimeric antibody having two antibodies that are non-covalently associated to form a tetravalent antibody dimer having four antigen-biding sites; neoplastic disorders such as colon cancer; autoimmune disorders
12/06/2007US20070280879 Therapeutic Use Of Rm1 Antigen
12/06/2007DE102006026464A1 Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus A pharmaceutical composition for the treatment of viral infections and / or tumors by inhibition of protein folding and protein degradation
12/06/2007DE102006026026A1 Arzneimittel Drug
12/06/2007DE102006025146A1 Peptide that modulates proteasome activity, e.g. for disease treatment, comprises a human protein sequence
12/06/2007DE102006025103A1 Spezifisch adaptierter pflanzlicher Redoxkatalysator, als Mittel zur Behandlung von Stoffwechselveränderungen und immunbiologischen Zellbelastungsschwächen sowie Verfahren zu dessen Herstellung Specifically adapted plant redox catalyst, as agents for the treatment of metabolic changes and immune cell biological stress weaknesses and method for its manufacture
12/06/2007CA2657276A1 Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
12/06/2007CA2655668A1 Aziridinyl-epothilone compounds
12/06/2007CA2654276A1 Pharmaceutical composition for treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein degradation
12/06/2007CA2653931A1 Immune-derived moieties reactive against lysophosphatidic acid
12/06/2007CA2653667A1 7-membered ring compound and method of production and pharmaceutical application thereof
12/06/2007CA2653662A1 Spirocyclic nitriles as protease inhibitors
12/06/2007CA2653474A1 Bioactive purified hspe7 compositions
12/06/2007CA2653472A1 Novel lapachone compounds and methods of use thereof
12/06/2007CA2653336A1 Method for treating non-hodgkin's lymphoma
12/06/2007CA2653329A1 Triazole compounds that modulate hsp90 activity
12/06/2007CA2653319A1 Hsp90 inhibitor
12/06/2007CA2653288A1 Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same
12/06/2007CA2653076A1 Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
12/06/2007CA2653005A1 Thiophene-carboxamides useful as inhibitors of protein kinases
12/06/2007CA2652926A1 Drug combinations with substituted diaryl ureas for the treatment of cancer
12/06/2007CA2652888A1 Methods and compositions using immunomodulatory compounds in combination therapy
12/06/2007CA2652167A1 Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
12/06/2007CA2652044A1 Pyrrolopyrimidine compounds and their uses
12/06/2007CA2651979A1 Triazolopyridazine derivatives
12/06/2007CA2651368A1 Tumor suppressor
12/06/2007CA2650510A1 Materials and complexes for the delivery of biologically-active material to cells
12/06/2007CA2647592A1 Inhibitors of polo-like kinases
12/05/2007EP1862546A1 Enhanced virus-mediated dna transfer
12/05/2007EP1862544A1 Polypeptides capable of eliciting an immune reaction against cancer
12/05/2007EP1862475A1 Polymer conjugates of neublastin and methods of using same
12/05/2007EP1862470A1 Element retained in blood showing degradability selectively in tumor tissue
12/05/2007EP1862457A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
12/05/2007EP1862451A1 Adamantane derivatives for the treatment of inflammatory diseases
12/05/2007EP1862450A2 Novel compounds
12/05/2007EP1862444A2 Ether compounds, compositions, and uses thereof
12/05/2007EP1862179A1 Novel use of sulfonamide compound in combination with angiogenesis inhibitor
12/05/2007EP1862178A1 Use of HLTF antibodies for diagnosis and treatment of cancer
12/05/2007EP1862169A1 Use of cis-rhenium (III) diadamantate compounds for potentiating the antitumoral activity of platinum complexes
12/05/2007EP1862168A1 Method of treating liver cancer
12/05/2007EP1862165A2 Prevention and treatment of androgen-deprivation induced hot flashes
12/05/2007EP1861425A2 Anti-mesothelin antibodies
12/05/2007EP1861407A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
12/05/2007EP1861403A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
12/05/2007EP1861402A1 Isoflavonoid dimers
12/05/2007EP1861381A1 Novel 3-aryl-1,2-benzisoxazole derivatives, compostions containing same and use thereof